Pharvaris N.V. (PHVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 303,776 | 335,590 | 369,995 | 399,909 | 423,430 |
| Receivables | 3,186 | 3,002 | 1,735 | 915 | 1,125 |
| Other current assets | 6,219 | 4,787 | 6,377 | 8,244 | 6,040 |
| TOTAL | $313,181 | $343,380 | $378,107 | $409,068 | $430,595 |
| Non-Current Assets | |||||
| PPE Net | 722 | 597 | 278 | 258 | 242 |
| Other Non-Current Assets | 1,394 | 391 | 518 | 629 | 670 |
| TOTAL | $2,116 | $988 | $796 | $887 | $913 |
| Total Assets | $315,297 | $344,368 | $378,903 | $409,955 | $431,507 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 4,938 | 4,614 | 3,197 | 6,035 | 3,149 |
| Accrued Expenses | 19,032 | 13,278 | 17,077 | 13,191 | 11,978 |
| TOTAL | $24,861 | $18,002 | $20,497 | $19,930 | $15,804 |
| Non-Current Liabilities | |||||
| TOTAL | $692 | $19 | $47 | $76 | $47 |
| Total Liabilities | $25,553 | $18,021 | $20,544 | $20,006 | $15,851 |
| Shareholders' Equity | |||||
| Common Shares | 7,061 | 7,156 | 6,979 | 7,012 | 6,791 |
| Retained earnings | -435,280 | -403,278 | -349,742 | -319,215 | -287,804 |
| Other shareholders' equity | 43,121 | 39,705 | 34,469 | 32,446 | 30,175 |
| TOTAL | $289,744 | $326,347 | $358,359 | $389,949 | $415,656 |
| Total Liabilities And Equity | $315,297 | $344,368 | $378,903 | $409,955 | $431,507 |